Ichor Biologics

Executive Summary

Ichor Biologics is a preclinical biotechnology company headquartered in San Diego, dedicated to developing novel antibody-based therapeutics for infectious diseases. The company's proprietary high-throughput platform enables the isolation and characterization of naturally occurring human monoclonal antibodies from individuals who demonstrate resistance to specific pathogens. Its lead programs are focused on hantavirus infections, a neglected area with significant unmet medical need. By leveraging the immune systems of resistant individuals, Ichor aims to rapidly advance immunotherapies that could provide effective treatments against these severe viral diseases. The company operates in the early stages of drug development and has not yet initiated clinical trials. Given its preclinical stage, Ichor Biologics faces typical risks associated with early biotechnology ventures, including scientific, regulatory, and financial uncertainties. However, its unique approach to antibody discovery from naturally resistant individuals provides a differentiated strategy that could yield high-affinity, broadly neutralizing antibodies. The company's progress will depend on successful IND-enabling studies, securing partnerships, and obtaining regulatory clearance to enter clinical testing. While the potential for breakthrough therapies exists, the timeline to commercialization remains long, and significant milestones lie ahead. Ichor's ability to advance its lead hantavirus program through preclinical development and into the clinic will be critical for value creation.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Hantavirus Antibody Candidate40% success
• Q4 2026Preclinical Efficacy Data Readout in Animal Models60% success
• TBDPartnership or Licensing Deal for Platform Technology30% success